To test our hypothesis that Wee1 inhibition sensitizes cells to EphA2-targeted therapy, we examined the anti-tumor effects of both agents in endometrial cancer mouse models and evaluated potential mechanisms of synergy. Here, EPHA2 is linked to neoplasm.